Cassandra Blohowiak is a contributing editor at Pharmaceutical Executive Magazine
Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
The latest state-level attempt to regulate pharma marketing is also the most stringent, requiring both drug and device manufacturers to track and disclose marketing spend. And the state's very important biotech industry is crying foul.
All signs point to Genentech acquisition.
Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.
Lilly's blood thinner earns approval in Europe and challenges Plavix's status as king of the ACS market.
After more reports surface that link Raptiva to a deadly brain infection, world drug regulation agencies decide the risks outweigh benefits.
Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year.
GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts.
Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough to get the biotech's board of directors to sign on the dotted line.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial